Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

Neumann, Anke; Weill, Alain; Ricordeau, P.; Fagot, Jean-Paul; Alla, François; Allemand, H.

doi:10.1007/s00125-012-2538-9

Cited by 255 publications

(287 citation statements)

References 16 publications

Supporting

Mentioning

272

Contrasting

Unclassified

Order By: Relevance

“…A nationwide and retrospective cohort study was carried out using a French national health insurance database (SNIIRAM) 25, 26, 27, 28, 29, 30, 31. This database contains anonymous individual data on all reimbursements for patient health expenditure, including medicinal products and outpatient medical and nursing care, prescribed or provided by healthcare professionals.…”

Section: Methodsmentioning

confidence: 99%

Short‐Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care

Bouillon¹,

Bertrand²,

Boudali³

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundSeveral studies have recently examined the risks of bleeding and of ischemic stroke and systemic embolism associated with perioperative heparin bridging anticoagulation in patients with nonvalvular atrial fibrillation. However, few studies have investigated bridging risks during vitamin K antagonist initiation in outpatient settings.Methods and ResultsA retrospective cohort study was conducted on individuals starting oral anticoagulation between January 2010 and November 2014 for nonvalvular atrial fibrillation managed in outpatient care and identified from French healthcare insurance. Bleeding and ischemic stroke and systemic embolism events were identified from the hospitalization database. Adjusted hazard ratios with 95% CI were estimated using Cox models during the first and 2 following months of anticoagulation. Of 90 826 individuals, 30% had bridging therapy. A total of 318 (0.35%) cases of bleeding and 151 (0.17%) ischemic stroke and systemic embolism cases were identified during the first month of follow‐up and 231 (0.31%) and 122 (0.16%) during the 2 following months, respectively. At 1 month of follow‐up, the incidence of bleeding was higher in the bridged group compared with the nonbridged group (0.47% versus 0.30%; P<0.001), and this increased risk persisted after adjustment for covariates (hazard ratio=1.60; 95% CI, 1.28–2.01). This difference disappeared after the first month of treatment (0.93; 0.70–1.23). No significant difference in the occurrence of ischemic stroke and systemic embolism was observed either at 1 month of follow‐up or later.ConclusionsAt vitamin K antagonist initiation for nonvalvular atrial fibrillation managed in ambulatory settings, bridging therapy is associated with a higher risk of bleeding and a similar risk of arterial thromboembolism compared with no bridging therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Short‐Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care

Bouillon¹,

Bertrand²,

Boudali³

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…There are reports of increased bone fractures, congestive heart failure and bladder cancer with the use of Pioglitazone which have raised concerns about its long-term safety. [81][82][83] Elafibranor is a dual PPAR α/Y receptor agonist which has been evaluated in the treatment of NASH. After exclusion of mild cases, high dose elafibranor (120 mg/ day) was better than placebo in the resolution of NASH.…”

Section: (B) Peroxisome Proliferator-activated Receptors (Ppar) Agonistsmentioning

confidence: 99%

NAFLD therapy and monitoring disease progression

Puri¹,

Va²

2017

View full text Add to dashboard Cite

“…The A4 Study plans to test the efficacy of solanezumab (a humanized monoclonal anti-Ab antibody) in 1000 clinically normal older individuals identified as at-risk for progression to AD dementia due to brain amyloid accumulation on positron emission tomography (PET) imaging [33]. Furthermore, some prevention trials are testing antiamyloid therapies in autosomal-dominant AD [34,35].…”

Section: Ad-specific Drugsmentioning

confidence: 99%

“…One RCT investigated the effect of the blockbuster NSAID rofecoxib [64], which was later withdrawn from the international market due to an increased risk of cardiovascular events. Last, the safety of pioglitazone tested in the very large TOMMOROW trial has been questioned [35,65] and this antidiabetic drug is no longer marketed in some countries (e.g., France).…”

Section: Safety Concernsmentioning

confidence: 99%

Prevention Studies in Alzheimer’s Disease: Progress Towards the Development of New Therapeutics

2015

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia and is a major cause of disability and dependency amongst older people. AD drugs approved so far are symptomatic treatments and are not thought to affect the underlying disease process. Trials conducted with agents aiming to slow or stop disease progression in patients with AD have all failed, perhaps because they were tested too late in the disease process. Therefore, there has been a move towards prevention of AD. This paper presents an overview of trials testing pharmacological interventions for sporadic AD prevention. Those tested to date were initially developed for the treatment of AD or for the treatment of other conditions, rather than being specifically developed for AD prevention. Associated issues, such as evidence of 'proof-of-concept,' doses and safety, are discussed. A major shift has taken place in the methodology of AD prevention trials since the results of the first trials were published in the 1990s. New directions that are currently being considered in ongoing or future prevention trials are discussed, in terms of endpoints, target populations, and study design. The use of AD-specific drugs to prevent AD in high-risk individuals is currently limited by a lack of validated predictive and surrogate markers. Population approaches, such as lifestyle changes, are an alternative strategy that could be of public health interest, but may provide only limited benefits for individuals. The best chance of preventing AD may come from a combination of individual and population prevention approaches. Key PointsFollowing the failure of treatment trials in symptomatic Alzheimer's disease (AD), there has been a move towards prevention of AD.To date, no specific pharmacological intervention has been developed for sporadic AD prevention and trial results have been disappointing.A major shift has taken place in the methodology of AD prevention trials and new directions are being considered in terms of endpoints, target populations, and study design.

show abstract

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

Cited by 255 publications

References 16 publications

Short‐Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care

Short‐Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care

NAFLD therapy and monitoring disease progression

Prevention Studies in Alzheimer’s Disease: Progress Towards the Development of New Therapeutics

Contact Info

Product

Resources

About